Go Pro
NASDAQ:SMTI

Sanara MedTech (SMTI) Stock Price, News & Analysis

Sanara MedTech logo
$33.86 -0.20 (-0.59%)
Closing price 07/31/2026 04:00 PM Eastern
Extended Trading
$33.66 -0.20 (-0.59%)
As of 07/31/2026 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Sanara MedTech Stock (NASDAQ:SMTI)

Advanced

Key Stats

Today's Range
$33.62
$34.00
50-Day Range
$20.81
$34.06
52-Week Range
$16.05
$35.95
Volume
576,545 shs
Average Volume
239,053 shs
Market Capitalization
$310.16 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$35.00
Consensus Rating
Hold

Company Overview

Sanara MedTech is a medical technology company focused on developing and commercializing innovative devices for ear, nose and throat (ENT) healthcare. The company’s core offering centers on minimally invasive sinus dilation systems designed to treat chronic sinusitis and related conditions. These products leverage balloon catheter technology to expand sinus pathways and improve patient outcomes while reducing recovery times. In addition to sinus solutions, the portfolio extends to procedural tools and implants for otology and cranial applications.

With its legacy rooted in the assets of a former Johnson & Johnson business, Sanara MedTech combines decades of research and development in ENT therapies. The company offers a range of balloon-based dilation products, including multi­sinus dilation systems, as well as adjunctive instruments for tissue access and endoscopic visualization. Its ENT platform is complemented by specialized energy‐based ablation technologies and implantable devices designed to address complex nasal and ear disorders.

Following its establishment through a business combination in early 2022, Sanara MedTech continues to invest in clinical studies and product enhancements aimed at broadening indications and improving procedural efficiency. The company collaborates with leading physicians and academic centers to validate its technologies and expand training programs that support adoption by surgeons worldwide.

Headquartered in Irvine, California, Sanara MedTech serves markets across North America, Europe, Latin America and Asia Pacific through a combination of direct sales teams and distributor partnerships. Its leadership team comprises experienced executives and clinicians with backgrounds in medical device innovation, regulatory affairs and global commercialization. Looking forward, the company is positioned to leverage its established technology platforms to pursue growth opportunities in ENT and adjacent specialties.

AI Generated. May Contain Errors.

Sanara MedTech Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
17th Percentile Overall Score

SMTI MarketRank™: 

Sanara MedTech scored higher than 17% of companies evaluated by MarketBeat, and ranked 830th out of 898 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Sanara MedTech has received a consensus rating of Hold. The company's average rating score is 2.20, and is based on 1 strong buy rating, no buy ratings, 3 hold ratings, and 1 sell rating.

  • Upside/Downside

    The consensus price target for Sanara MedTech is close to its current price, suggesting limited near-term upside or downside.

  • Amount of Analyst Coverage

    Sanara MedTech has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Sanara MedTech's stock forecast and price target.
  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Sanara MedTech is -8.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Sanara MedTech is -8.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Sanara MedTech has a P/B Ratio of 50.54. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Sanara MedTech's valuation and earnings.
  • Percentage of Shares Shorted

    7.10% of the float of Sanara MedTech has been sold short.
  • Short Interest Ratio / Days to Cover

    Sanara MedTech has a short interest ratio ("days to cover") of 7.22.
  • Change versus previous month

    Short interest in Sanara MedTech has recently increased by 4.41%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Sanara MedTech does not currently pay a dividend.

  • Dividend Growth

    Sanara MedTech does not have a long track record of dividend growth.

  • News Sentiment

    Sanara MedTech has a news sentiment score of 0.05. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.74 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 11 news articles for Sanara MedTech this week, compared to 3 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Sanara MedTech insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    42.00% of the stock of Sanara MedTech is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    8.10% of the stock of Sanara MedTech is held by institutions.

  • Read more about Sanara MedTech's insider trading history.
Receive SMTI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sanara MedTech and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

SMTI Stock News Headlines

Wall Street Zen Downgrades Sanara MedTech (NASDAQ:SMTI) to Buy
Here’s Why Trump Won’t End The Iran War
Trump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. One day it's a ceasefire, the next it's bombs again. The back and forth may be masking a bigger story most investors are missing. See the real reason this conflict may never fully end.tc pixel
Sanara MedTech agrees to be acquired by MiMedx
MIMEDX to Acquire Sanara MedTech
See More Headlines

SMTI Stock Analysis - Frequently Asked Questions

Sanara MedTech's stock was trading at $23.35 at the beginning of 2026. Since then, SMTI shares have increased by 45.0% and is now trading at $33.86.

Sanara MedTech Inc. (NASDAQ:SMTI) released its earnings results on Wednesday, November, 12th. The company reported $0.09 earnings per share for the quarter, topping analysts' consensus estimates of ($0.24) by $0.33. The business had revenue of $26.33 million for the quarter, compared to the consensus estimate of $26.63 million. Sanara MedTech had a negative trailing twelve-month return on equity of 3.19% and a negative net margin of 31.23%.
Read the conference call transcript
.

Shares of SMTI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Sanara MedTech investors own include Tesla (TSLA), Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Alphabet (GOOG).

Company Calendar

Last Earnings
11/12/2025
Today
8/01/2026
Next Earnings (Estimated)
8/12/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Healthcare Equipment & Supplies
Sub-Industry
Healthcare Supplies
Current Symbol
NASDAQ:SMTI
CIK
714256
Fax
N/A
Employees
60
Year Founded
1982

Price Target and Rating

High Price Target
$35.00
Low Price Target
$35.00
Potential Upside/Downside
+3.4%
Consensus Rating
Hold
Rating Score (0-4)
2.20
Research Coverage
5 Analysts

Profitability

EPS (Trailing Twelve Months)
($3.77)
Trailing P/E Ratio
N/A
Forward P/E Ratio
211.63
P/E Growth
N/A
Net Income
-$37.56 million
Net Margins
-31.23%
Pretax Margin
0.58%
Return on Equity
-3.19%
Return on Assets
-0.56%

Debt

Debt-to-Equity Ratio
6.59
Current Ratio
2.28
Quick Ratio
2.05

Sales & Book Value

Annual Sales
$103.12 million
Price / Sales
3.01
Cash Flow
$0.59 per share
Price / Cash Flow
56.95
Book Value
$0.67 per share
Price / Book
50.54

Miscellaneous

Outstanding Shares
9,160,000
Free Float
5,315,000
Market Cap
$310.16 million
Optionable
Not Optionable
Beta
1.18

Social Links

Don't Wait for the OpenAI IPO Cover

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

This page (NASDAQ:SMTI) was last updated on 8/2/2026 by MarketBeat.com Staff.
From Our Partners